Kimberly Clark Corp vs Zoetis Inc — how do they compare? Kimberly Clark Corp trades at $107.39 (market cap $36.01B), while Zoetis Inc trades at $75.15 (market cap $31.95B). The key difference: Kimberly Clark Corp and Zoetis Inc are close in size by market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| KMB | ZTS | |
|---|---|---|
Market Cap | $36.01B | $31.95B |
Sector | Consumer Staples | Health |
52-Week High | $136.77 | $156.76 |
52-Week Low | $93.05 | $71.91 |
Enterprise Value | $42.55B | $39.24B |
Dividend Yield | 4.72% | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $108.43, up 0.07% on the day, with a neutral technical signal and bullish moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.97 exceeding the $1.93 estimate. Revenue declined to $16.45B in 2025, but net income margin remains strong at 12.8%. Recent news highlights KMB's innovation strategy and its status as a Dividend King, with a 4.5% yield attracting income investors.
KMB offers stable income with a high dividend yield and solid fundamentals, but faces revenue pressure and competitive risks. Analyst consensus is a $115.33 price target with a hold-heavy rating. Key risks include consumer sentiment impacts and input cost inflation, while the pending Kenvue merger provides growth potential.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →